California healthcare providers are maintaining heightened awareness of mpox cases following state health officials’ warning about increased travel-related introductions of clade I mpox and a broader increase in clade II infections. The California Department of Public Health (CDPH) issued a June 2026 health update advising clinicians to maintain a heightened index of suspicion when evaluating patients with compatible symptoms, particularly when recent international travel or exposure to an international traveler is involved.
The development is relevant for physicians, urgent care providers, infectious disease specialists, sexual health clinicians, and other healthcare professionals who may encounter patients presenting with symptoms that overlap with other infectious conditions. California’s public health guidance emphasizes appropriate clinical assessment, testing, infection prevention, vaccination, and prompt reporting when clade I infection is suspected.
Mpox Cases Prompt Increased Clinical Vigilance
The increase in mpox cases has prompted California health authorities to reinforce clinical vigilance rather than suggesting that the disease represents a widespread risk to the general population. CDPH reported that travel-related introductions of clade I mpox increased in California during 2026, while clade II infections were also occurring at higher levels than in previous years.
For physicians, the development underscores the importance of incorporating travel history and relevant exposure information into clinical assessments. Patients presenting with compatible rashes, lesions, or other symptoms may require consideration for mpox testing depending on their clinical circumstances.
Maintaining awareness is particularly important because early symptoms can overlap with other infections and dermatologic conditions.
Travel History Becomes an Important Clinical Consideration
Travel exposure has become increasingly relevant to the evaluation of mpox cases in California. CDPH reported seven travel-related clade I cases in the state from January through June 2026, compared with five total clade I cases reported during 2024 and 2025 combined. The agency indicated that additional travel-related introductions could be expected.
Physicians are therefore encouraged to ask appropriate patients about recent international travel and potential close contact with people who have recently traveled. This information can help clinicians determine whether additional testing, infection-control precautions, or public health notification may be appropriate.
The emphasis on travel history does not mean that every symptomatic traveler has mpox. Rather, it provides clinicians with another relevant factor when assessing potential exposure.
Clade I and Clade II Require Continued Attention
California’s current situation involves both major mpox clades. CDPH has reported an increase in travel-related introductions of clade I while also documenting rising numbers of clade II infections within the state.
The distinction is clinically relevant because the two clades represent different viral lineages and may have different epidemiological patterns. CDPH notes that clade I has not been demonstrated to be more transmissible than clade II, while transmission studies continue.
Healthcare providers should therefore avoid relying solely on assumptions about the patient’s travel history or vaccination status when determining whether testing is appropriate.
Testing Remains Important for Symptomatic Patients
Testing plays an important role in identifying mpox cases, particularly when a patient presents with compatible signs and symptoms. CDPH recommends considering mpox testing for patients with compatible symptoms regardless of vaccination status or previous infection.
This guidance is significant for physicians because vaccination or prior infection does not necessarily eliminate the need for diagnostic evaluation when symptoms are clinically consistent with mpox.
Providers must also understand how laboratory results are interpreted. CDPH advises that an orthopoxvirus-positive result that is negative or indeterminate for clade II may indicate possible clade I infection and should prompt appropriate public health notification.
Infection Prevention Remains a Provider Priority
Healthcare facilities encountering suspected mpox cases must maintain appropriate infection-prevention procedures. CDPH’s June health update recommends full personal protective equipment for providers and relevant healthcare personnel when evaluating suspected clade I cases.
These precautions are particularly important because mpox can spread through direct contact with infectious lesions, body fluids, and contaminated materials. Transmission can also occur through close personal contact and shared living environments.
Healthcare organizations should ensure that staff understand current infection-control procedures and know when suspected cases require additional precautions or coordination with public health authorities.
Vaccination Continues to Support Prevention
Vaccination remains an important component of California’s response to rising mpox cases. CDPH recommends a two-dose mpox vaccine for people who may be at increased risk and indicates that vaccination is expected to provide protection against both clade I and clade II.
The department has also encouraged eligible Californians to remain current with vaccination, particularly as international travel and other exposure opportunities increase.
For physicians, discussing vaccination with appropriate patients can become an important part of preventive care and infectious disease risk assessment.
Public Health Reporting Remains Essential
Prompt reporting is another important component of managing mpox cases. CDPH instructs providers to immediately notify their local health department and/or the state health department when clade I mpox is suspected or confirmed.
Timely notification allows public health authorities to coordinate testing, case investigation, contact assessment, and post-exposure prevention when appropriate.
For healthcare organizations, clear internal protocols can help ensure suspected cases are escalated appropriately without creating unnecessary delays in clinical care.
Physicians Should Maintain a Broad Differential Diagnosis
The rise in mpox cases does not mean that every patient presenting with a rash or lesion has mpox. Physicians must continue considering a broad differential diagnosis based on clinical presentation, medical history, exposure information, and appropriate laboratory testing.
CDPH specifically advises clinicians to consider mpox among sexually active patients presenting with rash, lesions, or proctitis. The agency also recommends heightened suspicion for clade I among patients with compatible symptoms and recent international travel or close contact with an international traveler.
This approach allows clinicians to recognize potentially significant infections without unnecessarily narrowing the diagnostic process.
Healthcare Systems Continue Monitoring the Trend
Healthcare organizations across California are continuing to monitor mpox cases as public health officials evaluate transmission patterns and potential additional introductions. CDPH has noted that the number of clade II infections in 2026 is substantially higher than comparable periods in previous years, adding another reason for continued surveillance.
For healthcare leaders, ongoing monitoring can support workforce education, testing preparedness, infection-control planning, and vaccination outreach.
The situation also demonstrates the importance of maintaining flexible infectious disease protocols that can respond to changing epidemiological conditions.
Long-Term Outlook for Mpox Cases
The outlook for mpox cases in California will depend on travel-related introductions, community transmission, vaccination coverage, early diagnosis, and the effectiveness of public health surveillance. CDPH expects additional travel-related clade I introductions while continuing to monitor increasing clade II activity.
For physicians, continued awareness remains the most practical response. Maintaining appropriate travel and exposure histories, recognizing compatible symptoms, considering testing, following infection-control guidance, and reporting suspected clade I infections can help support California’s broader public health response.
As international travel and healthcare mobility continue, mpox will remain an issue that California clinicians should monitor as part of routine infectious disease preparedness.
Visit California Department of Public Health – Mpox Health Update to review the official guidance issued for California healthcare providers.
Subscribe to StanfordPhysicianAdvocate.org for continuing coverage of California healthcare policy, physician guidance, infectious disease developments, public health regulations, healthcare workforce issues, and clinical developments affecting medical professionals throughout 2026.